PDE3A cyclic nucleotide phosphodiesterases regulate cAMP-and cGMP-mediated intracellular signaling in cardiac myocytes. We used antibodies to different regions of PDE3A to demonstrate the presence of three PDE3A isoforms in these cells. These isoforms, whose apparent molecular weights are 136,000, 118,000, and 94,000 ("PDE3A-136," "PDE3A-118," and "PDE3A-94"), are identical save for the deletion of different lengths of N-terminal sequence containing two membrane-association domains and sites for phosphorylation/activation by protein kinase B ("PK-B") and protein kinase A ("PK-A"). PDE3A-136 contains both membrane-association domains and the PK-B and PK-A sites. PDE3A-118 contains only the downstream membrane-association domain and the PK-A sites. PDE3A-94 lacks both membrane localization domains and the PK-B and PK-A sites. The three isoforms are translated from two mRNAs derived from the PDE3A1 gene: PDE3A-136 is translated from PDE3A1 mRNA, whereas PDE3A-118 and PDE3A-94 are translated from PDE3A2 mRNA. Experiments involving in vitro transcription/translation indicate that PDE3A-118 and PDE3A-94 may be translated from different AUGs in PDE3A2 mRNA. These findings suggest that alternative transcriptional and post-transcriptional processing of the PDE3A gene results in the generation of two mRNAs and three protein isoforms in cardiac myocytes that differ with respect to intracellular localization and may be regulated through different signaling pathways.
PDE3 cyclic nucleotide phosphodiesterases bind cAMP and cGMP with high affinity and hydrolyze both substrates in a mutually competitive manner (1) . Two PDE3 genes have been discovered: PDE3A is expressed primarily in cardiac and vascular myocytes and platelets, whereas PDE3B is expressed primarily in adipocytes, hepatocytes, and pancreatic cells (2) . The functional topographies of the proteins corresponding to the longest ORFs 1 of PDE3A and PDE3B cDNAs are similar and include a C-terminal catalytic region ("CCR") of Ϸ280 amino acids and two N-terminal hydrophobic regions ("NHRs") that are involved in intracellular targeting (Fig. 1) . NHR1 (aa Ϸ60 -255) contains transmembrane helices, whereas NHR2 (aa Ϸ340 -400) appears to be involved in the binding of PDE3 to as yet unidentified membrane proteins. rtPDE3As containing NHR1 localize exclusively to intracellular membranes in transfected cells, whereas rtPDE3As containing NHR2 but not NHR1 are found in both the cytosol and intracellular membranes of transfected cells (3, 4) . Between NHR1 and NHR2 are sites for phosphorylation and activation by PK-B (site "P1," Ser 292 in PDE3A ORF) and PK-A (site "P2," Ser 312 ) (5-7). A second PK-A site whose function is unclear (site "P3," Ser 438 ) lies between NHR2 and CCR (8) . Phosphorylation of PDE3 by PK-B and PK-A and the accompanying stimulation of catalytic activity are important in the physiologic responses of adipocytes, oocytes, promyeloid cells, and platelets to a variety of extracellular signals (9 -13) .
PDE3 is particularly important in the cardiovascular system. PDE3 inhibitors (e.g. milrinone and enoximone) have inotropic effects attributable to the elevation of cAMP content in cardiac myocytes and vasodilatory effects attributable to the elevation of cAMP and/or cGMP content in vascular myocytes, and have been used to augment contractility and reduce afterload in patients with dilated cardiomyopathy (14) . Whereas the use of these drugs results in hemodynamic benefits in the short term, long-term use increases mortality. These biphasic actions probably reflect the broad range of proteins phosphorylated by PK-A in cardiac myocytes and the diverse cellular responses that are elicited.
Our previous studies indicated that multiple isoforms of PDE3A are present in cardiac and vascular myocytes and are localized to different intracellular compartments. One protein, with an apparent molecular weight ("M r ") of Ϸ136,000, was recovered exclusively in microsomal fractions; the other two, with lower molecular weights, were present in both cytosolic and microsomal fractions (15) . We subsequently identified two PDE3A mRNAs in cardiac and vascular myocytes: PDE3A1, whose cDNA was cloned from myocardium, contains an ORF of 1141 nt. PDE3A2, whose cDNA was cloned from aortic myocytes, shares the sequence of PDE3A1 starting Ϸ300 nt downstream from the latter's start site but lacks the sequence upstream of this site (16) . The PDE3A isoform translated from PDE3A2 in vascular myocytes had an apparent M r of only Ϸ118,000, comparable with one of the lower molecular * This work was supported by Medical Research Funds from the United States Department of Veterans Affairs. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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weight bands identified in human myocardium. The 136,000-M r PDE3 band was not present in cultured aortic myocytes.
The presence of different PDE3A isoforms in cytosolic and microsomal fractions of cardiac myocytes is especially interesting in view of the facts that cAMP metabolism in these compartments can be regulated with some independence in cardiac muscle and that changes in cAMP content in these compartments have different effects on intracellular Ca 2ϩ homeostasis and contractility (17) (18) (19) . In the experiments described below, we have identified three PDE3A isoforms in subcellular fractions of cardiac myocytes whose N-terminal amino acid sequence differences suggest that they differ with respect to mechanisms of intracellular targeting and that their activities may be regulated via different signaling pathways.
EXPERIMENTAL PROCEDURES
Preparation of rtPDE3A1-A human myocardial PDE3A construct was generated by inserting an 8-amino acid Flag epitope (Asp-Tyr-LysAsp-Asp-Asp-Asp-Lys) immediately upstream from the stop codon of the PDE3A1. Using 50 ng of PDE3A1 cDNA (20) as template (GenBank TM accession number NM_000921), PCR amplification was performed in a GeneAmp PCR system (PerkinElmer Life Sciences, Wellesley, MA) with Pfu polymerase (Stratagene, La Jolla, CA) using 3 pmol each of sense primer, CTTCATCTCTCACATTGTGGGGCCTCTGTG, corresponding nt 3009 -3027 of the PDE3A1 ORF, and antisense primer, TTTGCGGCCGCCTCGAGTTATTTATCATCATCATCTTTAT-AATCCTGGTCTGGCTTTTGGGTTGG, corresponding to nt 3423-3403 and the FLAG epitope. The resulting PCR product contained the unique PDE3 DraIII site at the 5Ј end and a stop codon at the 3Ј end; the stop codon is flanked upstream by a FLAG epitope-coding sequence and downstream by an XhoI site. The PCR products were subcloned into the pCRII vector (Invitrogen) and isolated from this vector as DraIII/XhoI fragments. XhoI/DraIII fragments containing the ORF sequence of PDE3A1 upstream from the unique DraIII site were restricted from pBluescript. In a three-way ligation, these 5Ј XhoI/DraIII fragments were ligated via the DraIII site to the 3Ј DraIII/XhoI FLAG epitopecontaining fragments and to XhoI-cut pZero vector (Invitrogen), to give PDE3A1 Flag-pZero. PDE3A1-Flag was then excised from pZero with XhoI, ligated into pAcSG2 vector, subcloned, and amplified.
PDE3A1-Flag-pAcSG2 plasmid (2 g) was co-transfected with linearized BaculoGold DNA into Sf21 cells (BaculoGold transfection kit; Pharmingen, San Diego, CA). After 5 days, fresh Sf21 cells, (10 -20) ϫ 10 6 cells/75-cm 2 flask, grown in TNM-FH medium (Pharmingen, San Diego, CA), were infected with medium containing PDE3A1-Flag baculovirus. For amplification, 100 -500 l of medium was collected after 72-96 h and used to infect fresh cultures, after which viral titers were determined by a 12-well end point dilution assay according to the manufacturer's instructions. Cells from 75 cm 2 flasks, usually 10 -20 ϫ 10 6 cells per flask, were sedimented for 10 min at 1000 ϫ g, washed twice with ice-cold phosphate-buffered saline, and resuspended in 10 mM HEPES, 1 mM EDTA, 250 mM sucrose, 10 mM pyrophosphate, 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1% Nonidet P-40, and 10 g/ml each of aprotinin, leupeptin, and pepstatin. Lysates were prepared by sonication on ice (two 20-s pulses, output 2, 40% of cycle) with a Sonifier cell disruptor 350 (Branson Sonic Power, Danbury, CT). Lysates were sedimented for 10 min at 12,000 ϫ g; supernatant fractions were used for Western blotting.
Preparation of Subcellular Fractions-Cytosolic and KCl-washed microsomal fractions, from the left ventricular myocardium of the explanted hearts of cardiac transplant recipients with idiopathic dilated cardiomyopathy, were prepared by homogenization, differential sedimentation, and high-salt washing as described previously (21) . Each preparation was made from tissue pooled from at least three different hearts. Comparable fractions of cultured human aortic myocytes (Clonetics, seventh passage) were prepared as described previously (16) .
Western Blotting-Lysates of Sf21 cells expressing rtPDE3A1 and subcellular fractions of human myocardium and aortic myocytes were precipitated with trichloroacetic acid (final concentration 50%), dissolved in SDS buffer, subjected to SDS-PAGE (8% acrylamide), and transferred electrophoretically to nitrocellulose membranes (Schleicher & Schuell). Western blotting was performed with antibodies that were raised against peptides corresponding to aa 29 -42, 424 -460, and 1125-1141 of the ORF of PDE3A1 as described previously (16) .
Expression of rtPDE3A1 Isoforms by in Vitro Transcription/Translation-The entire coding region of PDE3A1 cDNA was inserted into pBluescript as previously described (16) . In addition, a plasmid with an ATGATG to CTGCTG mutation (Met-Met 3 Leu-Leu) at nt 1450 -1455 was generated by PCR using QuikChange site-directed mutagenesis (Stratagene); the primers used for mutagenesis were 5Ј-GGAATAATC-CAGTGCTGCTGACCCTCACCAAAAGCAGATCC-3Ј (sense) and its complementary antisense primer (corresponding to nt 1436 -1476 of the PDE3A1 ORF). After amplification in Escherichia coli (XL1-Blue), mutated plasmids were purified using a QIAprep Spin Miniprep kit (Qiagen, Valencia, CA) and sequenced.
PCR products with different 5Ј deletions were generated from the wild-type and mutated pBluescript-PDE3A1 plasmids using five sense primers containing T7 promoter sites immediately upstream from genespecific sequences and an antisense primer containing the stop codon and a poly(A) tail (Table I) . In vitro translation products were synthesized from the PCR fragment templates and labeled with 4 Ci of [ 35 S]methionine (1000 Ci/mmol) in reticulocyte lysates using the TNT T7 Quick for PCR DNA system (Promega).
5Ј-RACE-PCR amplification was performed on Marathon RACEReady cDNA from human myocardium (Clontech) using 1 pmol of gene-specific antisense primer and 1 pmol of sense primer corresponding to the 5Ј end of the manufacturer's 5Ј tag. A second round of PCR was performed for 35 cycles using 1 pmol of nested gene-specific primer and 1 pmol of nested sense primer corresponding to a second sequence within the manufacturer's tag. RACE products were purified on agarose gels and ligated into pCR2.1 vector with T4 ligase (14°C, overnight) using a TA cloning kit (Invitrogen). Competent cells (INV␣FЈ) were transformed using a One Shot Kit (Invitrogen) and plated on 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-gal) LB-ampicillin plates (100 g/ml ampicillin). Positive colonies were grown overnight in LBampicillin medium. Plasmids were purified using the Mini-or Midiprep Plasmid purification systems (Qiagen) and inserts were excised with EcoRI. Insert sizes were estimated by electrophoresis through agarose gels.
Southern and Northern Blotting-DNA probes were prepared from PDE3A1 plasmid by PCR using region-specific primers. PCR products were purified using QIA Quick kits (Qiagen). DNA was labeled with TAATACGACTCACTATAGGGACTGCA GGAAGCACCTTCATCCAGTCC
[␣-32 P]dCTP (3000 Ci/mmol, 10 mCi/ml) using a random primer labeling kit (Stratagene). Unincorporated nucleotides were removed using Sephadex G-50 (fine) columns (Roche Molecular Biochemicals).
For Southern blotting, linear DNA corresponding to nt Ϫ268 to nt 2610 of PDE3A1 ORF was prepared from PDE3A1 template by PCR and purified as described above. The PCR product was quantified by measurement of the A 260 /A 280 ratio and its purity confirmed by agarose gel electrophoresis. PCR product samples were subjected to electrophoresis on 0.7% agarose gels, transferred to Gene Screen Plus Nylon Membranes (PerkinElmer Life Sciences), cross-linked, and pre-hybridized for 2-3 h in QuikHyb (Stratagene). Labeled DNA probes were hybridized with DNA blots at 65°C for 3-4 h using 1.25 ϫ 10 6 cpm/ml of probe and 0.1 mg/ml salmon sperm DNA. Following hybridization, excess radiolabeled probe was removed by rinsing in SSC, 0.1% SDS and autoradiography was performed at Ϫ80°C.
For Northern blotting, RNA was extracted from human left ventricular myocardium from the excised hearts of transplant recipients with dilated cardiomyopathy using TRI reagent (Molecular Research Center, Cincinnati, OH). Poly(A) RNA was prepared from total RNA using a Message Maker kit (Invitrogen). RNA was quantified and its purify confirmed as described above. Poly(A) RNA samples were subjected to electrophoresis on 1% agarose, 0.5 M formaldehyde gels, transferred to GeneScreen Plus Nylon membranes, cross-linked, and pre-hybridized for 2-3 h in QuikHyb. Labeled DNA probes were hybridized with RNA blots, excess radiolabeled probe was removed, and autoradiography performed as described for Southern blotting.
RESULTS

Identification of PDE3 Protein Isoforms in Cardiac
Myocytes-Polyclonal antibodies raised against synthetic peptides whose sequences correspond to selected regions of PDE3A1 ORF, including aa 29 -42 (N-terminal, or "NT"), aa 424 -460 ("MID"), and aa 1125-1141 (C-terminal, or "CT"), the extreme C terminus (16), were used for Western blotting of lysates of Sf21 cells expressing rtPDE3A1 and of cytosolic and microsomal fractions of human myocardium (Fig. 2) . All three antibodies reacted with rtPDE3A1 bands in Sf21 lysates. Anti-CT reacted with proteins in cytosolic and microsomal fractions of human myocardium with apparent M r of 94,000 and 118,000 and with a protein with an apparent M r of 136,000 seen only in microsomal fractions. Anti-MID reacted with the 118-and 136-kDa proteins but not with the 94-kDa protein. Anti-PDE3-NT did not react with any protein bands in these fractions.
The presence of multiple immunoreactive PDE3A bands might have resulted from the activation of tissue proteases during the preparation of subcellular fractions of human myocardium. To examine this possibility, we added 35 S-labeled rtPDE3A to a fresh homogenate of human myocardium, prepared cytosolic and microsomal fractions, and subjected these fractions to SDS-PAGE. Autoradiograms showed the same 35 Slabeled proteins bands in tissue fractions as in original Sf21 lysates (Fig. 3) , compatible with the notion that the three PDE3 bands identified in subcellular fractions of cardiac myocytes are not the result of proteolysis during the preparation of subcellular fractions.
These results suggested that the isoforms of PDE3A in cardiac muscle, which we have designated PDE3A-136, PDE3A-118, and PDE3A-94, the numbers corresponding to their apparent M r on SDS-PAGE, all contain the same C-terminal amino acid sequences downstream of different N-terminal starting points. Unexpectedly, the N terminus predicted by the PDE3A1 ORF was absent from PDE3A-136, the longest PDE3A isoform we identified, despite the fact that the apparent M r of this isoform on SDS-PAGE is greater than the M r predicted by the amino acid sequence of the PDE3A1 ORF. To gain insight into this apparent discrepancy, we compared the migration of native PDE3 isoforms on SDS-PAGE to the migration of rtPDE3As generated by in vitro transcription/translation from constructs with 5Ј deletions designed to result in translation from different in-frame AUGs (Fig. 4) . All rtPDE3A isoforms migrated with apparent M r ϳ20,000 higher than predicted by their amino acid sequences. The apparent M r of PDE3A-136 (lane 6) was slightly higher than the apparent M r of 131,000 for the rtPDE3A translated from AUG2 in the PDE3A1 ORF (lane 2), implying that PDE3A-136 contains part of NHR1 (consistent with its recovery only in microsomal fractions), all of NHR2, and the sites for phosphorylation and activation by PK-B and PK-A. The apparent M r of PDE3A-118 (lanes 7 and 8) was indistinguishable from that of the rtPDE3A translated from AUG4 (lane 4), implying that PDE3A-118 lacks NHR1 and the PK-B site but includes NHR2 and the PK-A sites. The apparent M r of PDE3A-94 (lanes 7 and 8) was slightly lower than the apparent M r of 95,000 for the rtPDE3A translated from AUG7/8 (lane 5), implying that PDE3A-94 contains neither of the membrane-association domains nor any of the three phosphorylation sites.
The absence of NHR1 from PDE3A-118, the isoform we orig- S-labeled rtPDE3A1 from reticulocyte lysates were added to 1 g of human myocardium and 5 ml of sucrose buffer, from which cytosolic and microsomal fractions were prepared. 5 l of reticulocyte lysates (control) and 20 l each of cytosolic and microsomal fractions were subjected to SDS-PAGE, of which the autoradiogram is shown. Numbers at the left indicate migration of M r markers.
inally identified in vascular myocytes, contradicts our predicted amino acid sequence for this isoform, which included NHR1 (16). This earlier prediction was based on the assumption that the apparent molecular weights of PDE3s on SDS-PAGE correspond to the molecular weights derived from their amino acid sequences, which our current results demonstrate to be incorrect. The absence of NHR1 from PDE3A-118 is consistent with its presence in both cytosolic and microsomal fractions.
Possible Generation of PDE3A-94 by Alternative Post-transcriptional Processing-In addition to the higher molecular weight bands discussed above, transcription/translation in vitro from every rtPDE3A construct generated a rtPDE3A isoform with an apparent M r of 95,000, similar to that of the AUG7/8 translation product. To examine the possibility that this 95,000 M r rtPDE3A might be generated from larger constructs by translation from AUG7/8, we prepared a construct starting from ATG1 in which ATG7/8 was mutated to CTGCTG (Met-Met 3 Leu-Leu). Expression of the mutated construct resulted in the disappearance of the 95,000 M r rtPDE3A (Fig.  5) , consistent with its generation from the longer mRNA by translation from AUG7/8.
PDE3A mRNAs in Human Myocardium-We turned our attention to identifying the mRNAs from which these three PDE3A protein isoforms are translated. Our previous studies (16) had shown that a PDE3A2 mRNA, whose sequence is identical to that of the PDE3A1 cDNA downstream of nt Ϸ300 in the latter's ORF but which lacks the latter's upstream sequence, is present in both cardiac and vascular myocytes, although PDE3A1 mRNA is present in cardiac but not in vascular myocytes. Whether PDE3A2 mRNA contained an alternative 5Ј sequence upstream of nt Ϸ300 remained unknown. To search for any such sequence, we performed 5Ј-RACE of a human myocardial cDNA library using three pairs of antisense primers derived from the shared sequence of PDE3A1 and PDE3A2 (Table II) . Subcloning and sequencing of multiple 5Ј-RACE products yielded no alternative upstream sequence. These results are similar to those obtained when 5Ј-RACE was performed with comparable primers in a human aortic cDNA library (16) .
We proceeded to perform Northern blotting on poly(A) RNA from human left ventricular myocardium using probes derived from different regions of the PDE3A1 ORF (Fig. 6) . Three cDNA probes were used. The first, derived from nt Ϫ268 -189, corresponds to a region predicted to be present in PDE3A1 but not PDE3A2; the other two cDNA probes correspond to nt 517-957 and 2248 -2610 of PDE3A1, regions predicted to be present in both PDE3A1 and PDE3A2. All three probes bound to an 8.2-kb band. The two downstream probes also bound to a 6.9-kb band to which the upstream probe did not bind. These results are consistent with the 8.2-kb band being PDE3A1 and the 6.9-kb band being PDE3A2. Their size differences can be accounted for by the absence of the first Ϸ300 nt of the ORF of PDE3A1 from PDE3A2, consistent with the generation of the S-labeled rtPDE3A proteins and native cardiac and aortic isoforms of PDE3A. A, rtPDE3A isoforms were generated by in vitro transcription/translation from constructs with 5Ј deletions designed to result in translation from different in-frame AUGs in the PDE3A1 ORF. B, 35 S-labeled rtPDE3A isoforms generated by in vitro transcription/translation and cytosolic and microsomal fractions of human myocardium were subjected to SDS-PAGE. The first five columns show autoradiograms of SDS-PAGE of 35 S-labeled rtPDE3As (5 l from each 50-l reaction mixture were added to each lane). The last three columns show Western blots of membranes prepared by electrophoretic transfer of lanes containing myocardial microsomes (50 g), myocardial cytosolic fraction (20 g), and aortic microsomes (100 g) from the same SDS-polyacrylamide gel with the antibodies listed. The predicted and apparent molecular weights of rtPDE3A isoforms are depicted below. latter by alternative transcription or splicing within exon 1. This absence of Ϸ300 nt of PDE3A1 in PDE3A2 was previously predicted by ribonuclease protection assays of RNA prepared from human myocardium and cultured human aortic myocytes with antisense probes spanning nt 208 -537 and 2248 -2610 of PDE3A1 (16) . The fact that PDE3A1 mRNA and PDE3A-136 are present only in cardiac myocytes while PDE3A2 mRNA and PDE3A-118 and PDE3A-94 are present in both cardiac and vascular myocytes is consistent with PDE3A1 mRNA giving rise to PDE3A-136 and PDE3A2 mRNA giving rise to both PDE3A-118 and PDE3A-94 (Fig. 7) . DISCUSSION An important feature of cAMP-mediated signaling in cardiac myocytes is its intracellular compartmentation. cAMP content in cytosolic and microsomal fractions of cardiac myocytes is affected differently depending on whether cAMP formation is stimulated via ␤ 1 -adrenergic, ␤ 2 -adrenergic, or PGE1 receptor agonists. These compartment-selective changes in cAMP content are accompanied by different effects on the phosphorylation of individual substrates of PK-A, intracellular Ca 2ϩ homeostasis, and contractility (17) (18) (19) . In addition, increases in the phosphorylation of different PK-A substrates occur when intracellular cAMP content is increased by phosphodiesterase inhibition rather than by stimulation of adenylate cyclase activity, and different cellular responses are elicited (22, 23) . This compartmentation of cAMP-mediated signaling is involved in the pathophysiology of dilated cardiomyopathy, where the reduction in cAMP content in failing myocardium is far greater in microsomal fractions than in cytosolic fractions (24) . Recent studies demonstrating differences in the spatial distribution of subtypes of ␤-adrenergic receptors in cardiac myocyte membranes have offered one mechanism through which compartment-selective regulation may occur (25) . Our identification of three isoforms of PDE3A with N-terminal differences involving membrane-association domains and sites for phosphorylation by activating protein kinases in cardiac myocytes offers an additional mechanism, for it suggests that these isoforms are likely to regulate cAMP content in functionally distinct intracellular compartments, and hence to regulate the phosphorylation of different substrates of PK-A, in response to different upstream signals.
Our findings may have important ramifications regarding 6 . Identification of PDE3A mRNAs in human myocardium. cDNA probes corresponding to different regions of PDE3A were prepared. The relation of the probes to the nucleotide sequences of PDE3A1 and PDE3A2 cDNAs is shown in panel A. ORFs are represented as blocks, whereas the 5Ј-and 3Ј-untranslated regions are represented as lines. The numbers for each probe correspond to the nucleotide sequence of PDE3A1 represented. (Nt 1 represents the first nucleotide in the longest ORF of PDE3A1; a negative number indicates that the probe begins in the 5Ј-untranslated region.) B, poly(A) RNA from human myocardium (0.5-2.0 g/lane) was subjected to electrophoresis and transfer followed by Northern blotting using cDNA probes as described. As a control, the same probes were used for Southern blotting of a linearized DNA fragment (5.0 pg/lane) corresponding to nt Ϫ268 to 2610 of the PDE3A1 ORF. the therapy of dilated cardiomyopathy, in which competitive inhibitors of PDE3 confer short term hemodynamic benefits but adversely affect long term survival (14) . This biphasic response is likely to result from an increase in the phosphorylation of a large number of PK-A substrates, some of which may contribute to the beneficial effects whereas others contribute to the adverse effects. Phosphorylation of phospholamban, for example, relieves its inhibition of SERCA2, the Ca 2ϩ -transporting ATPase of the sarcoplasmic reticulum (26, 27) . Ablation of phospholamban in cardiac myocytes of MLP Ϫ/Ϫ mice with dilated cardiomyopathy restores normal chamber size and contractility, whereas decreasing phospholamban expression in myocytes from failing hearts improves contractility (28, 29) . These observations suggest that increased phosphorylation of phospholamban is beneficial. In contrast, phosphorylation of L-type Ca 2ϩ channels increases their open probability and may be arrhythmogenic (30) , whereas phosphorylation of proteins in the mitogen-activated protein kinase cascade may alter myocardial gene transcription so as to speed the progression of the disease (31) . If different isoforms of PDE3A regulate the phosphorylation of different proteins in response to different signals, the beneficial and adverse effects of PDE3 inhibition may result from the inhibition of different PDE3A isoforms. A logical corollary is that agents capable of selectively activating or inhibiting individual PDE3 isoforms may have advantages over currently available nonselective PDE3 inhibitors in therapeutic applications. An agent that selectively inhibits sarcoplasmic reticulum-associated PDE3A-136, for example, might preserve intracellular Ca 2ϩ cycling and contractility in patients taking ␤-adrenergic receptor antagonists, without concomitant arrhythmogenic effects. On the other hand, PDE3A-136 is the only isoform containing the site for phosphorylation and activation by PK-B, an anti-apoptotic effector in cardiac myocytes (32) (33) (34) . The phosphorylation and stimulation of PDE3A-136 by PK-B may therefore be an anti-apoptotic event, and deleterious long term effects of PDE3 inhibition in dilated cardiomyopathy might be related specifically to inhibition of this isoform. If so, selective PDE3A-136 activators might be useful therapeutic agents. Experiments designed to identify the specific PK-A substrates whose phosphorylation is regulated by individual PDE3A isoforms are a logical next step in extending our observations. At a more basic level, our observations regarding the two PDE3A mRNAs in cardiac and vascular myocytes and the N-terminal deletions in the three PDE3A protein isoforms indicate that the specific mechanisms by which the latter are generated from their cognate mRNAs are complex. PDE3A-136 migrates on SDS-PAGE with an apparent molecular weight higher than that of the rtPDE3A generated from ATG2 but lower than that of the rtPDE3A generated from ATG1. PDE3A-136 may therefore be generated from PDE3A1 either by translation from AUG1 followed by targeted N-terminal proteolysis or by translation from AUG2 followed by some post-translational modification that reduces its electrophoretic mobility. Similarly, PDE3A-118 might be generated from PDE3A2 mRNA by translation from AUG4, the third AUG in the ORF predicted by the cloned cDNA (16), or by translation from AUG2 or AUG3 followed by targeted N-terminal proteolysis, whereas PDE3A-94 could be generated from PDE3A2 mRNA either by translation from AUG7/8 or by translation from a more upstream AUG followed by proteolytic removal of a more extensive length of N-terminal sequence. The possibility that PDE3A-118 and PDE3A-94 are generated from the same mRNA by alternative translational processing in vivo seems plausible given our observation that a PDE3A-94-like protein is generated from longer constructs by translation from downstream AUGs in vitro. Furthermore, a paradigm exists in the case of the PDE4 family of cyclic nucleotide phosphodiesterases: these enzymes have structurally similar C-terminal catalytic regions, but differences in their N-terminal sequences resulting from alternative splicing result in differences in intracellular targeting, regulation by phosphorylation, and protein-protein interactions (35) (36) (37) (38) . On the other hand, proteolysis of the N terminus of PDE4A5 by caspase-3 during apoptosis removes an Src homology 3-binding domain and alters its intracellular distribution, and this example may be a paradigm for the generation of PDE3A isoforms by targeted proteolysis (39) . Other investigators have identified a protein resembling PDE3A-94 in placenta that is translated from a third PDE3A mRNA, PDE3A3, that is generated from the PDE3A gene by transcription from a site downstream from the PDE3A2 start site (40) . Our data do not indicate that this mRNA, which is ϳ4.4 kb in length, is present in cardiac myocytes. These considerations are of therapeutic interest because agents capable of altering the transcription or translation of individual PDE3A isoforms may have the same advantages as agents capable of selectively activating or inhibiting their activities. For this reason, further delineation of the transcriptional, translational, and/or post-translational mechanisms through which the generation of PDE3A mRNAs and proteins are regulated is an important future direction.
